DE 120

Drug Profile

DE 120

Alternative Names: DE-120

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Santen Incorporated
  • Class Eye disorder therapies
  • Mechanism of Action Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 08 Apr 2015 Santen plans a phase II trial in Age-related macular degeneration in USA (Intravitreous) (NCT02401945)
  • 01 Apr 2015 Phase-II clinical trials in Wet age-related macular degeneration in USA (Intravitreous) (NCT02401945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top